# Infectious Diseases Referral

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Arthur Ashe (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML013-SYN-TD
- Date: 1989-01-12
- Fictional facility: St. Posthumous Health Center
- Fictional author: Vivian Tolliver, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- To: Priyanka Rao, MD, Infectious Diseases
- Urgency: Routine, within four weeks, on the same day as his four-week primary care visit

## Referral question

HIV infection diagnosed four months ago with cerebral toxoplasmosis and a CD4 count of 58, in a 45-year-old man who also has coronary artery disease after two bypass operations. Please review his antiretroviral regimen and its interactions with his cardiac medicines, and advise on opportunistic-infection prophylaxis, the monitoring schedule, and vaccines, so that we can co-manage his care. **S**

## Questions for the consultant

1. Is bictegravir, emtricitabine, and tenofovir alafenamide the right long-term regimen for him, given his coronary disease and his cardiac medicines, and which antiretroviral drugs should he avoid?
2. How long should trimethoprim-sulfamethoxazole maintenance continue, and does he need any other prophylaxis?
3. What monitoring schedule do you advise for viral load, CD4 count, and drug safety, and how should we read the rise in his creatinine?
4. Which vaccines does he need now, and which should wait for immune recovery?
5. Does his HIV infection change the plan for his coronary risk factors?

## Pertinent history

Admitted four months ago with right-hand weakness; MRI showed a single ring-enhancing left frontoparietal lesion, and stereotactic biopsy showed Toxoplasma. HIV was diagnosed during that admission, with a viral load of 186,000 copies/mL and a CD4 count of 58. The genotype showed no resistance mutations; hepatitis B surface antigen, surface antibody, and core antibody were negative; hepatitis C antibody negative; hepatitis A antibody positive; interferon-gamma release assay negative; Toxoplasma IgG positive. He completed six weeks of pyrimethamine, sulfadiazine, and leucovorin, and has taken trimethoprim-sulfamethoxazole double strength twice daily since. Bictegravir, emtricitabine, and tenofovir alafenamide were started two weeks into toxoplasmosis treatment. His right hand has recovered. Today, after about 15 weeks of therapy: viral load 42 copies/mL, CD4 156, hemoglobin 13.0 g/dL, potassium 4.9 mmol/L, creatinine 1.18 mg/dL (0.98 before treatment), ALT 30, LDL 88 mg/dL. Coronary disease: myocardial infarction at 36, quadruple bypass the same year, and a double bypass for recurrent angina at 39, with a blood transfusion during that operation; no angina now. He takes aspirin 81 mg and atorvastatin 80 mg, ezetimibe was added today, and he has sublingual nitroglycerin. PCV20, a first hepatitis B vaccine dose, and a first meningococcal ACWY dose were given today. He has asked that his diagnosis and results be shared with no one without his consent. **S**

- Arthur Robert Ashe Jr. was born in Richmond, Virginia, on July 10, 1943, to Mattie Cunningham Ashe and Arthur Robert Ashe Sr.; his mother died before he was seven. **D**
- On July 31, 1979, while teaching tennis to inner-city youth, Ashe had a heart attack, and he then underwent quadruple coronary artery bypass surgery in 1979. **D**
- When chest pain recurred, Ashe had a second bypass operation, a double bypass, in 1983, during which he received a blood transfusion. **D**
- In 1988 Ashe had difficulty moving his right hand and arm; a scan showed a mass in the left side of his brain, which surgeons removed, and the diagnosis was toxoplasmosis. Testing then showed that he had HIV and AIDS. **D**
- Ashe and his doctors concluded that he had almost certainly acquired HIV from a blood transfusion during his 1983 heart operation, before blood was tested for the virus. **D**
- Both of Ashe's parents had atherosclerotic heart disease at early ages. His mother died at 27 of complications from surgery, and his father had two heart attacks, at 55 and at 59. **D**

2 later historical claims are omitted because they describe events after the index age. See the teaching note.

Baseline: HIV-1 viral load: 42 {copies}/mL (high); CD4 count: 156 /uL (low); White cell count: 4.2 10*3/uL; Hemoglobin: 13 g/dL (low); Platelets: 198 10*3/uL; Sodium: 139 mmol/L; Potassium: 4.9 mmol/L; Creatinine: 1.18 mg/dL; eGFR: 78 mL/min/1.73 m²; Glucose: 92 mg/dL; ALT: 30 U/L; Total cholesterol: 158 mg/dL; HDL cholesterol: 40 mg/dL; Triglycerides: 150 mg/dL (high); LDL cholesterol: 88 mg/dL; HbA1c: 5.4%; PHQ-9: 5; AUDIT-C: 1. All results are synthetic.

BP 118/74 mmHg; pulse 72 bpm; respirations 14/min; temperature 36.7 °C; oxygen saturation 98% on room air; weight 72 kg; BMI 21 kg/m². All vital signs are synthetic.

## Current medications

- Bictegravir 50 mg, emtricitabine 200 mg, and tenofovir alafenamide 25 mg, one tablet by mouth once daily; take two hours before or six hours after antacids, calcium, iron, or magnesium **S**
- Sulfamethoxazole 800 mg and trimethoprim 160 mg (double strength), one tablet by mouth twice daily **S**
- Aspirin 81 mg delayed-release oral tablet, one tablet by mouth daily **S**
- Atorvastatin 80 mg oral tablet, one tablet by mouth daily **S**
- Ezetimibe 10 mg oral tablet, one tablet by mouth daily **S**
- Nitroglycerin 0.4 mg sublingual tablet, one tablet under the tongue every 5 minutes as needed for chest pain, up to 3 tablets; call 911 if pain is not better 5 minutes after the first tablet **S**

## Plan so far

- Antiretroviral therapy with bictegravir, emtricitabine, and tenofovir alafenamide once daily, chosen for its high barrier to resistance and few interactions with his cardiac medicines; viral load and CD4 count every three months. Guideline: Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents With HIV (current online edition); Antiretroviral Drugs for Treatment and Prevention of HIV in Adults: 2024 Recommendations of the International Antiviral Society-USA Panel (2024); Primary Care Guidance for Persons With Human Immunodeficiency Virus: 2020 Update by the HIV Medicine Association of the Infectious Diseases Society of America (2020) **S**
- Toxoplasma maintenance therapy with trimethoprim-sulfamethoxazole double strength twice daily, which also prevents Pneumocystis pneumonia, until the CD4 count is above 200 for more than six months on suppressive therapy; blood count, potassium, and creatinine every three months while on it. Guideline: Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents With HIV: Toxoplasma gondii encephalitis and Pneumocystis pneumonia sections (current online edition) **S**
- Secondary prevention of coronary disease after two bypass operations: aspirin, high-intensity atorvastatin with ezetimibe added for an LDL goal below 55 mg/dL, blood pressure below 130/80, a heart-healthy diet, regular exercise, and a written chest-pain plan with sublingual nitroglycerin. Guideline: 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease (2023); CMID: Clinical Monitoring Intelligence Database, ischemic heart disease and hyperlipidemia monographs (2026) **S**
- Vaccines for adults with HIV: pneumococcal, hepatitis B with an antibody check afterwards, the two-dose meningococcal ACWY series, recombinant zoster, and seasonal influenza and COVID-19, with no live vaccines while the CD4 count is below 200. Guideline: Primary Care Guidance for Persons With Human Immunodeficiency Virus: 2020 Update by the HIV Medicine Association of the Infectious Diseases Society of America (2020); Adult Immunization Schedule by Medical Condition and Other Indication (2026) **S**
- Person-first, confidential care: he decides who learns of his diagnosis; support with disclosure if and when he chooses, peer support, and depression screening with the PHQ-9 at intake and six months and the PHQ-2 at the preventive visit. Guideline: Primary Care Guidance for Persons With Human Immunodeficiency Virus: 2020 Update by the HIV Medicine Association of the Infectious Diseases Society of America (2020); Depression and Suicide Risk in Adults: Screening (2023); CMID: Clinical Monitoring Intelligence Database, ischemic heart disease and hyperlipidemia monographs (2026) **S**
